Tasman Therapeutics

Executive Summary

Tasman Therapeutics is advancing R-107, a novel oral extended-release ketamine tablet designed to transform the treatment landscape for major depressive disorders, including treatment-resistant depression (TRD). Unlike currently approved ketamine therapies that require intravenous infusion or intranasal administration, R-107 offers a convenient oral formulation with extended-release kinetics, potentially improving patient compliance, reducing the burden of clinic visits, and enabling more stable therapeutic effects. The company has successfully navigated early-stage clinical development and is now in Phase 3 trials, positioning R-107 as a first-in-class oral ketamine treatment. With a large and growing market—depression affects over 20 million Americans annually, and a significant portion do not respond to standard antidepressants—R-107 addresses a critical unmet need. Tasman is actively seeking strategic investors to fund the pivotal Phase 3 program and subsequent regulatory filings, with the goal of capturing a substantial share of the multibillion-dollar depression therapeutics market. The company's competitive advantage lies in its proprietary extended-release formulation, which has the potential to optimize pharmacokinetics, minimize side effects, and differentiate R-107 from existing rapid-acting antidepressants. If successfully commercialized, R-107 could become the preferred oral option for TRD, offering patients a more accessible and less invasive treatment alternative. However, the path to approval requires successful completion of Phase 3 trials, followed by NDA submission and FDA review. Given the high unmet need and the product's differentiated profile, Tasman Therapeutics represents a compelling investment opportunity in the psychedelic and neuropsychiatric space, albeit with typical clinical-stage risks. The company's experienced management team and focus on a large, validated target market further support its potential for significant value creation upon approval.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 Top-Line Data Readout55% success
• Q2 2027Strategic Partnership or Licensing Deal40% success
• Q3 2027NDA Submission45% success